Urate-LRRK2 interactions in Parkinson's disease
尿酸盐-LRRK2在帕金森病中的相互作用
基本信息
- 批准号:10640903
- 负责人:
- 金额:$ 38.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAlbuterolAnimal ModelAntioxidantsAstrocytesAttenuatedBehaviorBiological MarkersCaffeineCell modelClinicalCoculture TechniquesCorpus striatum structureDependenceDevelopmentDiseaseDisease modelDrug TargetingEnvironmental ExposureEnvironmental Risk FactorEpidemiologyEquilibriumFoundationsFumaratesFunctional disorderGenesGeneticGovernmentHumanIdiopathic Parkinson DiseaseInduced MutationInflammatoryInheritedInosineInvestigationInvestmentsKnock-outLRRK2 geneLaboratoriesLaboratory StudyLeadLinkMediatingMediatorModelingModificationMolecularMultiple SclerosisMusMutationNerve DegenerationNeurobiologyNeurodegenerative DisordersNeuronsOnset of illnessOther GeneticsOutcomeParkinson DiseasePathogenicityPathway interactionsPatientsPenetrancePersonsPesticidesPharmacologic SubstancePhenotypePhosphotransferasesPlayPositioning AttributeProcessPropertyReproducibilityRiskRisk FactorsRoleSafetySerumSignal TransductionTestingTherapeuticToxic effectTransgenesTransgenic OrganismsUrateUrate Oxidasebrain cellclinical developmentclinical practiceclinically relevantcohortcost effectivenessdemographicsdisorder riskdopaminergic neurondrug testingefficacy trialepidemiologic dataepidemiology studyexperimental studyhigh riskin vivo Modelinsightmouse LRRK2 proteinmutantneuroprotectionneurotoxicitynuclear factor-erythroid 2overexpressionpersonalized medicineprotective effectpurine metabolismresponsetherapeutic developmenturinary
项目摘要
Urate-LRRK2 interactions in Parkinson’s disease
Project Summary/Abstract:
Although mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are the most common
known genetic cause of Parkinson’s disease (PD), their incomplete penetrance indicates that other
genetic and environmental factors play important protective roles in LRRK2 PD. Classical epidemiology
studies of PD have identified molecular factors that may contribute to or protect against the underlying
neurodegenerative process. Among the latter, urate an endogenous antioxidant as well as the end
product of purine metabolism has emerged as a major inverse (reduced) risk factor not only for PD
onset but also for its clinical progression. A convergence of these epidemiological data with laboratory
evidence of its neuroprotective properties suggests that urate may be a mediator as well as a marker
of favorable outcomes in idiopathic PD. New biomarker findings of lower urate levels among LRRK2 PD
patients compared to people with LRRK2 mutations who have not developed PD raise the possibility
that higher levels of endogenous urate contribute to the incomplete penetrance of LRRK2 mutations.
The hypothesis is strengthened by evidence that urate protects dopaminergic neurons by activating the
Nrf2 antioxidant response pathway, which has recently been implicated in LRRK2 pathophysiology. The
current project will determine the neuroprotective potential and molecular mechanisms of urate in
laboratory models and human biomarker studies of LRRK2 PD. Through its specific aims (SAs) it will
characterize the neuroprotective effects of urate and their astrocyte dependence in cellular and animal
models of neurodegeneration in a LRRK2+ PD (SA 1). The role of Nrf2 in the neuroprotective actions
of urate and another Nrf2 activator, dimethyl fumarate (a pharmaceutical, approved for disease
modification in multiple sclerosis) will be incisively addressed through a complementary set Nrf2
knockout and Nrf2 transgene rescue studies in LRRK2+ PD models (SA 2). Lastly, the interaction
between urate and LRRK2 kinase activity (gauged by levels of auto-phosphorylated LRRK2) will be
explored in clinical cohorts of idiopathic and LRRK2 PD (SA 3). The mechanistic and clinical insights
generated by these studies may validate Nrf2 activation as a promising therapeutic strategy in LRRK2
PD, and may thereby facilitate early steps toward personalized medicine for PD. The results may also
help address a growing concern over cost-effectiveness in the field of personalized medicine because
Nrf2 activators are already available for clinical use. And of those poised for efficacy trials in LRRK2 PD
the urate precursor inosine has been developed as a non-proprietary therapeutic with foundation and
government investment. Thus the project offers realistic prospects for advancing our understanding of
PD neurobiology and treatment.
帕金森病中的尿酸-LRRK 2相互作用
项目概要/摘要:
虽然编码富含亮氨酸重复序列激酶2(LRRK 2)的基因突变是最常见的,
帕金森氏病(PD)的已知遗传原因,他们的不完全遗传表明,
遗传和环境因素在LRRK 2 PD中起重要的保护作用。经典流行病学
PD的研究已经确定了可能有助于或保护免受潜在疾病的分子因素。
神经退化过程在后者中,尿酸盐是一种内源性抗氧化剂,
嘌呤代谢产物已成为PD的主要反向(降低)风险因素,
发病,但也为临床进展。这些流行病学数据与实验室数据的融合
其神经保护特性的证据表明,尿酸盐可能是一种介质以及标记物,
在特发性PD中的有利结果。LRRK 2 PD中尿酸盐水平较低的新生物标志物发现
与未发生PD的LRRK 2突变患者相比,
高水平的内源性尿酸盐导致LRRK 2突变的不完全转移。
尿酸盐通过激活多巴胺能神经元保护多巴胺能神经元的证据加强了这一假设。
Nrf 2抗氧化反应途径,最近已被牵连在LRRK 2的病理生理学。的
目前的项目将确定尿酸盐的神经保护潜力和分子机制,
LRRK 2 PD的实验室模型和人类生物标志物研究。通过其具体目标,
表征尿酸盐的神经保护作用及其在细胞和动物中的星形胶质细胞依赖性
LRRK 2 + PD中的神经变性模型(SA 1)。Nrf 2在神经保护作用中的作用
尿酸盐和另一种Nrf 2激活剂,富马酸二甲酯(一种药物,批准用于疾病
在多发性硬化症的修改)将通过一个互补集Nrf 2
在LRRK 2 + PD模型中的敲除和Nrf 2转基因拯救研究(SA 2)。最后,互动
尿酸盐和LRRK 2激酶活性之间的关系(通过自磷酸化LRRK 2的水平来衡量)将是
在特发性和LRRK 2 PD的临床队列中进行了研究(SA 3)。机械和临床的见解
这些研究产生的结果可能会验证Nrf 2激活作为LRRK 2中有前途的治疗策略
PD,并因此可能促进早期步骤向个性化药物PD。结果还可能
有助于解决个性化医疗领域日益增长的成本效益问题,
nrf 2激活剂已经可用于临床。在那些准备进行LRRK 2 PD疗效试验的患者中,
尿酸盐前体肌苷已经被开发为一种非专有的治疗剂,
政府投资因此,该项目提供了现实的前景,以促进我们的理解,
PD神经生物学和治疗。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons.
短期脂多糖治疗导致 LRRK2 G2019S 敲入小鼠中的星形胶质细胞活化,且多巴胺能神经元不丢失。
- DOI:10.21203/rs.3.rs-4076333/v1
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Ngo,HoangKieuChi;Le,Hoang;Ayer,SamuelJ;Crotty,GraceF;Schwarzschild,MichaelA;Bakshi,Rachit
- 通讯作者:Bakshi,Rachit
The PSG 32nd Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders.
PSG 第 32 届帕金森病和其他运动障碍的病因、发病机制和治疗年度研讨会。
- DOI:10.1002/mds.29002
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Planning for Prevention of Parkinson Disease: Now Is the Time.
- DOI:10.1212/wnl.0000000000200789
- 发表时间:2022-08-16
- 期刊:
- 影响因子:9.9
- 作者:
- 通讯作者:
What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs.
- DOI:10.1212/wnl.0000000000200238
- 发表时间:2022-08-16
- 期刊:
- 影响因子:9.9
- 作者:
- 通讯作者:
The STEPWISE study: study protocol for a smartphone-based exercise solution for people with Parkinson's Disease (randomized controlled trial).
- DOI:10.1186/s12883-023-03355-8
- 发表时间:2023-09-12
- 期刊:
- 影响因子:2.6
- 作者:Schootemeijer, Sabine;de Vries, Nienke M.;Macklin, Eric A.;Roes, Kit C. B.;Joosten, Hilde;Omberg, Larsson;Ascherio, Alberto;Schwarzschild, Michael A.;Bloem, Bastiaan R.
- 通讯作者:Bloem, Bastiaan R.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL A SCHWARZSCHILD其他文献
MICHAEL A SCHWARZSCHILD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL A SCHWARZSCHILD', 18)}}的其他基金
Planning for Prevention of Parkinson's Disease: a trial design forum
帕金森病预防规划:试验设计论坛
- 批准号:
10827547 - 财政年份:2023
- 资助金额:
$ 38.55万 - 项目类别:
2019 Parkinson Study Group Symposium and Training
2019年帕金森研究组研讨会及培训
- 批准号:
9763271 - 财政年份:2019
- 资助金额:
$ 38.55万 - 项目类别:
Urate-LRRK2 interactions in Parkinson's disease
尿酸盐-LRRK2在帕金森病中的相互作用
- 批准号:
10427325 - 财政年份:2019
- 资助金额:
$ 38.55万 - 项目类别:
Urate-LRRK2 interactions in Parkinson's disease
尿酸盐-LRRK2在帕金森病中的相互作用
- 批准号:
9978147 - 财政年份:2019
- 资助金额:
$ 38.55万 - 项目类别:
Urate-LRRK2 interactions in Parkinson's disease
尿酸盐-LRRK2在帕金森病中的相互作用
- 批准号:
10210454 - 财政年份:2019
- 资助金额:
$ 38.55万 - 项目类别:
2019 Parkinson Study Group Symposium and Training
2019年帕金森研究组研讨会及培训
- 批准号:
9890023 - 财政年份:2019
- 资助金额:
$ 38.55万 - 项目类别:
2017 Parkinson Study Group Symposium and Training
2017年帕金森研究组研讨会及培训
- 批准号:
9398499 - 财政年份:2017
- 资助金额:
$ 38.55万 - 项目类别:
Phase 3 trial of inosine for Parkinson's disease CCC
肌苷治疗帕金森病 CCC 的 3 期试验
- 批准号:
9292399 - 财政年份:2015
- 资助金额:
$ 38.55万 - 项目类别:
Phase 3 trial of inosine for Parkinson's disease CCC
肌苷治疗帕金森病 CCC 的 3 期试验
- 批准号:
9258571 - 财政年份:2015
- 资助金额:
$ 38.55万 - 项目类别:
Phase 3 trial of inosine for Parkinson's disease CCC
肌苷治疗帕金森病 CCC 的 3 期试验
- 批准号:
9129755 - 财政年份:2015
- 资助金额:
$ 38.55万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 38.55万 - 项目类别:
Research Grant